Fig. 1: Genomic landscape of RAD51B-associated cancers.

A Recurrent (present in ≥2 samples) nonsynonymous somatic mutations identified in 18 tumors from patients with germline RAD51B mutations using targeted massively parallel sequencing (MSK-IMPACT; n = 8) or whole-exome sequencing (WES; n = 8). Phenobar provides information on RAD51B germline mutations, dominant mutational signatures and cancer type. Loss of heterozygosity (LOH) of the RAD51B wild-type allele is displayed by a white diagonal line. B Large-scale transition (LST) scores in biallelic RAD51B-associated cancers, monoallelic RAD51B-associated cancers, biallelic BRCA1-associated cancers and biallelic BRCA2-associated cancers from TCGA.